contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Antti discussed Bioretec’s new strategy and financial goals with Bioretec CEO Sarah Hubar-Fisher.                    Inderes              Bioretec: Tavoitteita laskettiin (eng.) - Inderes    Aika: 18.12.2025 klo 17.39 Bioretec päivitti strategiansa ja taloudelliset tavoitteet vuosille 2026–28. Yhtiö leikkasi vuoden 2028 liikevaihtotavoitettaan 10 MEUR:oon (aik. 65 MEUR). Bioretecin toimitusjohtaja Sarah Hubar-Fisher haastattelussa.                             Topics: 00:00 Introduction  00:08 New strategy  03:03 What has changed?  05:52 US development  08:12 Distribution channels outside the US  10:55 Revenue targets  12:56 Gross margin  14:51 Profitability development  18:03 Potential partners  20:28 New product launches  23:08 Year 2026

Antti has written a new company report on Bioretec, following these companies’ new “updates”.  Bioretec updated its strategy and financial targets for 2026–28. The company cut its 2028 revenue target to 10 MEUR (prev. 65 MEUR). The turnaround in earnings has also moved further away, and the company does not expect profitability during the strategy period. We are lowering our forecasts, especially regarding earnings for the coming years. Our target price is lowered to EUR 0.65 (prev. 1.05) and our recommendation is lowered to Reduce (prev. Accumulate) following the forecast changes.                   Inderes              Bioretec: Tuloskäänne karkaa kauemmas - Inderes    Bioretec päivitti strategiansa ja taloudelliset tavoitteet vuosille 2026–28.

Bioretec’s products are very good, and there seems to be a continuous active approach to their development work. Marketing is understandably quite different from that of a weight loss drug or a cancer drug, which, if successful, are quickly absorbed into the market. On the other hand, once these products gain a foothold in surgery, I believe the market will be stable and grow sustainably. In my opinion, the strategy and goals are now realistic, and what could be better than if they can be exceeded. I believe that a new foundation is now being built, and they don’t want to cause new disappointments for investors. Some larger cooperation or acquisition is also reasonably likely. The obvious need for financing understandably creates uncertainty. I will definitely keep my position.

If revenue reaches 10 million in three years, then the company has succeeded in something, meaning the growth slope would have increased. 2025 is roughly flat, so if we reach that 10 million, it’s good. Of course, the old targets were on a completely different scale, but so was the share price. I personally expect the new CEO to actually achieve something, otherwise, the patents will expire. If it drops to 50c, then the risk of someone buying it out increases, so I’ll buy then at the latest, otherwise I’ll just watch.  By the way, that unfortunately shows what the CEOs (whom I already declared terrible at the time) achieved. What a waste. The new CEO does seem better, but I’m waiting for proof. Growth 21-22 40% 22-23 30% 23-24 10% 24-25 0%

Financial Goals: In line with the strategy and the priorities for the 2026-2028 period, Bioretec’s new financial goals are:   Achieve a turnover of over 10 million euros by the end of 2028   Maintain an average sales margin of over 70% throughout the strategy period   A new three-year target and over 10 million in turnover  Now hundreds of millions have been forgotten, and the management team is pulling expectations straight into a pit and then pulling the rug out from under our feet. Well, if there’s anything good, that target is already possible to exceed if things go well, and the ‘Reset’ button has now been pressed for Bioretec’s story. From here, we start building from scratch. In the short term, the new guidance is a disaster.

Here are Antti’s comments regarding this latest release.   Bioretec announced on Sunday that the U.S. Food and Drug Administration (FDA) has granted its RemeOs-DrillPin Breakthrough Device Designation status. The news is a positive indication of the company’s technology potential and supports the product’s future marketing authorization process, but it does not solve the company’s short-term commercial challenges. The announcement has no immediate impact on our forecasts.                   Inderes              Bioretec sai läpimurtostatuksen - Inderes    FDA myönsi RemeOs-DrillPinille Breakthrough Device Designation -statuksen.

Something positive for a change. Bioretec has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation status. Time will tell if that turns into money at some point.                   Bioretec              Tiedotteet | Bioretec    Bioretec on suomalainen, globaalisti toimiva lääkinnällisiä laitteita valmistava yhtiö ja biohajoavien ortopedisten implanttien edelläkävijä. Yhtiöllä on ainutlaatuista materiaalitekniikan ja biokemian yhdistävää osaamista aktiivisista implanteista,...

Bioretec

Bioretec Ltd Managers' transactions 8 January 2024 at 17.00 p.m. EETBioretec Oy - Managers' Transactions____________________________________________Person subject to the notification requirementName...

<div class="abstract">Bioretec Ltd&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Managers' transactions 8 January 2024 at 17.00 p.m. EET</div>Bioretec Oy - Managers' Transactions____________________________________________Person subject to the notification requirementName: Michael PiccirilloPosition: Member of the Board/Deputy memberIssuer: Bioretec OyLEI: 7437008736AG7HY51K13Notification type: INITIAL NOTIFICATIONReference number: 48797/7/6____________________________________________Transaction date: 2023-01-13Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000480454Nature of transaction: ACQUISITIONTransaction details(1): Volume: 7553 Unit price: 2.05 EURAggregated transactions (1):Volume: 7553 Volume weighted average price: 2.05 EURFurther enquiriesTimo Lehtonen, CEO, tel. +358 50 433 8493Johanna Salko, CFO, tel. +358 40 754 8172Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29Information about BioretecBioretec is a globally operating Finnish medical device company that continues to pioneer the Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.Better healing - Better life. www.bioretec.com&nbsp;(<a href="https://bioretec-my.sharepoint.com/personal/johanna_salko_bioretec_com/Documents/Desktop/Tiedottaminen/Yhti%C3%B6tiedotteet/26.4.2023/www.bioretec.com">https://bioretec-my.sharepoint.com/personal/johanna_salko_bioretec_com/Documents/Desktop/Tiedottaminen/Yhtiötiedotteet/26.4.2023/www.bioretec.com</a>)